Lucemyra (lofexidine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	MBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESCRIFOLLOWING LINK: PRIMETHERAPEUTICS.COM,	IBER, YOU WILL NEED TO SUBMIT A PHI DISCLO NOPP	HT (LB/KG): ALLERGI	JEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):			

Prime

Continued on next page.

Lucemyra (lofexidine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	BER'S LAST NAME: MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHI	ER MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Acute phase of opioid withdrawl		
□ Other diagnosis:	ICD-10:	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION. Clinical Information:	N: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
	E phase of opioid withdrawl? Yes I	No
Will patient be treated with any other	er agent(s) for acute opioid withdrawl wh	nile taking Lucemvra? □ Yes □ No
	atment of the CHRONIC phase of opioid	
I	nyra? Yes No If patient has starte e patient has starte e patient has been on Lucemyra therapy	
Are there any other comments, diagonal physician feels is important to this re	noses, symptoms, medications tried or factions?	illed, and/or any other information the
Please note: Not all drugs/diagnosis a information is received.	ire covered on all plans. This request may	be denied unless all required
the Health Plan, insurer, Medical Grou	on provided is true and accurate to the be up or its designees may perform a routine ccuracy of the information reported on th	audit and request the medical
	. Verification:	
you are not the intended recipient, you are he	companying this transmission contain confidential ereby notified that any disclosure, copying, distribu u have received this information in error, please no	tion, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.